Last reviewed · How we verify
NCT06841692: U-TUBE 2
Diuretic Testing in Chronic Kidney Disease
NA trial testing Diuretic Testing in Kidney Disease, Chronic in 86 participants. Currently enrolling.
31 October 2029
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 86 |
| Start date | 1 April 2025 |
| Primary completion | 31 October 2029 |
| Estimated completion | 31 October 2029 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Diuretic Testing
Conditions studied
- Kidney Disease, Chronic — all drugs for Kidney Disease, Chronic →
Sponsor
Erasmus Medical Center
Who can join
18 and older, any sex, with Kidney Disease, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease? If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney. Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06841692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Disease, Chronic
Currently open trials in the same condition.
- NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
- NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
- NCT06701825 — Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus · Phase 4 · recruiting
- NCT06830473 — KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection · recruiting
- NCT06863194 — Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial · Phase 1, PHASE2 · recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06841692 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06841692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing